Analgesics
Antiandrogens
Antihistamines
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Monoclonals
Mpro inhibitors
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Quercetin
RdRp inhibitors
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
next
study
previous
study
c19early.org COVID-19 treatment researchN-acetylcysteineN-acetylcys.. (more..)
Metformin Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta
Ivermectin Meta Thermotherapy Meta
Melatonin Meta

All Studies   Meta Analysis       

A Retrospective Analysis of Outcomes Amongst COVID-19 Infected Patients with Acute Hepatitis Receiving N-Acetylcysteine Therapy in a Safety Net Hospital

Pellegrini et al., Gastroenterology, doi:10.1016/S0016-5085(21)02756-6
May 2021  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Mortality 52% Improvement Relative Risk N-acetylcysteine  Pellegrini et al.  LATE TREATMENT Is late treatment with N-acetylcysteine beneficial for COVID-19? Retrospective 864 patients in the USA (March - May 2020) Lower mortality with N-acetylcysteine (p=0.00014) c19early.org Pellegrini et al., Gastroenterology, May 2021 FavorsN-acetylcysteine Favorscontrol 0 0.5 1 1.5 2+
14th treatment shown to reduce risk in February 2021, now with p = 0.000028 from 24 studies, recognized in 3 countries.
Lower risk for mortality, hospitalization, and cases.
No treatment is 100% effective. Protocols combine treatments.
5,300+ studies for 116 treatments. c19early.org
Retrospective 864 hospitalized late stage COVID-19 patients in the USA, 138 receiving NAC treatment for acute hepatitis, showing lower mortality with treatment. Results are adjusted for confounders, however details are not provided.
Standard of Care (SOC) for COVID-19 in the study country, the USA, is very poor with very low average efficacy for approved treatments1. Only expensive, high-profit treatments were approved. Low-cost treatments were excluded, reducing the probability of treatment—especially early—due to access and cost barriers, and eliminating complementary and synergistic benefits seen with many low-cost treatments.
risk of death, 51.7% lower, OR 0.48, p < 0.001, treatment 138, control 726, adjusted per study, inverted to make OR<1 favor treatment, multivariable, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Pellegrini et al., 23 May 2021, retrospective, USA, peer-reviewed, 10 authors, study period March 2020 - May 2020.
This PaperN-acetylcys..All
Abstract: Powered by TCPDF (www.tcpdf.org)
DOI record: { "DOI": "10.1016/s0016-5085(21)02756-6", "ISSN": [ "0016-5085" ], "URL": "http://dx.doi.org/10.1016/s0016-5085(21)02756-6", "alternative-id": [ "S0016508521027566" ], "author": [ { "affiliation": [], "family": "Pellegrini", "given": "James R.", "sequence": "first" }, { "affiliation": [], "family": "Munshi", "given": "Rezwan F.", "sequence": "additional" }, { "affiliation": [], "family": "Russe-Russe", "given": "Jose R.", "sequence": "additional" }, { "affiliation": [], "family": "Berman", "given": "Lorin", "sequence": "additional" }, { "affiliation": [], "family": "George", "given": "Reshma", "sequence": "additional" }, { "affiliation": [], "family": "Veeramani", "given": "Swarna", "sequence": "additional" }, { "affiliation": [], "family": "Kagolanu", "given": "Deepthi", "sequence": "additional" }, { "affiliation": [], "family": "Srivastava", "given": "Pranay", "sequence": "additional" }, { "affiliation": [], "family": "Rizvon", "given": "Kaleem", "sequence": "additional" }, { "affiliation": [], "family": "Mustacchia", "given": "Paul", "sequence": "additional" } ], "container-title": [ "Gastroenterology" ], "content-domain": { "crossmark-restriction": false, "domain": [] }, "created": { "date-parts": [ [ 2021, 5, 10 ] ], "date-time": "2021-05-10T15:20:22Z", "timestamp": 1620660022000 }, "deposited": { "date-parts": [ [ 2021, 9, 24 ] ], "date-time": "2021-09-24T13:40:27Z", "timestamp": 1632490827000 }, "indexed": { "date-parts": [ [ 2021, 12, 9 ] ], "date-time": "2021-12-09T07:29:59Z", "timestamp": 1639034999386 }, "is-referenced-by-count": 0, "issn-type": [ { "type": "print", "value": "0016-5085" } ], "issue": "6", "issued": { "date-parts": [ [ 2021, 5 ] ] }, "journal-issue": { "issue": "6", "published-print": { "date-parts": [ [ 2021, 5 ] ] } }, "language": "en", "license": [ { "URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "content-version": "tdm", "delay-in-days": 0, "start": { "date-parts": [ [ 2021, 5, 1 ] ], "date-time": "2021-05-01T00:00:00Z", "timestamp": 1619827200000 } } ], "link": [ { "URL": "https://api.elsevier.com/content/article/PII:S0016508521027566?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://api.elsevier.com/content/article/PII:S0016508521027566?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining" } ], "member": "78", "original-title": [], "page": "S-848", "prefix": "10.1016", "published": { "date-parts": [ [ 2021, 5 ] ] }, "published-print": { "date-parts": [ [ 2021, 5 ] ] }, "publisher": "Elsevier BV", "reference-count": 0, "references-count": 0, "relation": {}, "score": 1, "short-container-title": [ "Gastroenterology" ], "short-title": [], "source": "Crossref", "subject": [ "Gastroenterology", "Hepatology" ], "subtitle": [], "title": [ "Su320 A RETROSPECTIVE ANALYSIS OF OUTCOMES AMONGST COVID-19 PATIENTS WITH ACUTE HEPATITIS RECEIVING N-ACETYLCYSTEINE THERAPY IN A SAFETY NET HOSPITAL" ], "type": "journal-article", "volume": "160" }
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit